Agilent Technologies Inc (A) : Cardinal Capital Management scooped up 586 additional shares in Agilent Technologies Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 58,653 shares of Agilent Technologies Inc which is valued at $2,451,695.Agilent Technologies Inc makes up approximately 1.01% of Cardinal Capital Management’s portfolio.
Agilent Technologies Inc opened for trading at $41.35 and hit $41.75 on the upside on Wednesday, eventually ending the session at $41.58, with a gain of 0.63% or 0.26 points. The heightened volatility saw the trading volume jump to 11,89,462 shares. Company has a market cap of $13,629 M.
Other Hedge Funds, Including , Valley National Advisers Inc added A to its portfolio by purchasing 38 company shares during the most recent quarter which is valued at $1,588. Clean Yield Group added A to its portfolio by purchasing 213 company shares during the most recent quarter which is valued at $8,714.
On the company’s financial health, Agilent Technologies Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.43. The company had revenue of $1.03 million for the quarter, compared to analysts expectations of $1016.10 million. During the same quarter in the previous year, the company posted $0.41 EPS.
Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.